This analysis reports survival trends and disparities in primary mediastinal B cell lymphoma, highlighting improvements associated with chemotherapy and targeted therapies.
Key Points
To analyze survival trends and prevalence disparities in primary mediastinal B-cell lymphoma.
Extracted cases using ICD Code 9679/3 from SEER database (2000-2022)
Stratified data by age, gender, race, income, and treatment modalities
Compared survival curves using Log-Rank test
Total of 1460 PMBCL cases found from 2000 to 2022
1-year OS was 94.5%, 3-year OS 88.2%, and 5-year OS 86.9%
Declining mortality-to-incidence ratio from 25.7% to 7.1% over the study period
Higher survival associated with younger age, Hispanic ethnicity, and chemotherapy management